Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report

Objective: The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the opt...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	JTO Clinical and Research Reports
المؤلفون الرئيسيون:	Yichen Dong, MD, Long Xu, MD, Jialiang Wen, MD, Haojie Si, MD, Juemin Yu, MD, Tao Chen, MD, Huikang Xie, MD, Xinjian Li, MD, Minglei Yang, MD, Junqiang Fan, MD, Junqi Wu, MD, Yunlang She, MD, Deping Zhao, MD, Chang Chen, MD, PhD
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2025-01-01
الموضوعات:	Non-small cell lung cancer Neoadjuvant chemoimmunotherapy Adjuvant immunotherapy Perioperative immunotherapy
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2666364324001334